# Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)

> **NCT02518672** · PHASE2 · TERMINATED · sponsor: **SCF Pharma** · enrollment: 11 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DIETARY_SUPPLEMENT:** MAG-DHA
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT02518672
- **Lead sponsor:** SCF Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2016-03
- **Final completion:** 2016-11
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-10-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02518672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02518672, "Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02518672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*